6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Lactic	JJ	lactic	lactic	lactic	N	B-AdverseReaction
Acidosis	NNP	acidosis	acidosis	acidosi	Y	I-AdverseReaction
Severe	NNP	severe	severe	sever	N	B-Severity
Hepatomegaly	NNP	hepatomegaly	hepatomegaly	hepatomegali	Y	B-AdverseReaction
with	IN	with	with	with	N	O
Steatosis	NNP	steatosis	steatosis	steatosi	N	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Severe	NNP	severe	severe	sever	N	B-Severity
Acute	NNP	acute	acute	acut	N	B-AdverseReaction
Exacerbations	NNP	exacerbations	exacerbation	exacerb	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
Hepatitis	NNP	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
B	NNP	b	b	b	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

New	NNP	new	new	new	N	B-AdverseReaction
Onset	NNP	onset	onset	onset	N	I-AdverseReaction
or	CC	or	or	or	N	O
Worsening	NNP	worsening	worsening	worsen	N	B-AdverseReaction
Renal	NNP	renal	renal	renal	N	I-AdverseReaction
Impairment	NNP	impairment	impairment	impair	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Bone	NNP	bone	bone	bone	N	B-AdverseReaction
Effects	NNPS	effects	effect	effect	N	I-AdverseReaction
of	IN	of	of	of	N	O
Tenofovir	NNP	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
Reconstitution	NNP	reconstitution	reconstitution	reconstitut	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
to	TO	to	to	to	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
10%	CD	10%	10%	10%	N	O
,	,	,	,	,	N	O
all	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
nausea	JJ	nausea	nausea	nausea	Y	B-AdverseReaction
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Gilead	NNP	gilead	gilead	gilead	N	O
Sciences	NNPS	sciences	science	scienc	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
GILEAD	NNP	gilead	gilead	gilead	N	O
-	:	-	-	-	N	O
5	CD	5	5	5	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
from	IN	from	from	from	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
Infected	VBN	infected	infected	infect	N	O
Subjects	NNS	subjects	subject	subject	N	O
With	IN	with	with	with	N	O
No	DT	no	no	no	N	O
Antiretroviral	NNP	antiretroviral	antiretroviral	antiretrovir	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
History	NNP	history	history	histori	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
assessment	NN	assessment	assessment	assess	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
Week	NNP	week	week	week	N	O
144	CD	144	144	144	N	O
pooled	VBD	pooled	pooled	pool	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
1408	CD	1408	1408	1408	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
two	CD	two	two	two	N	O
randomized	NNS	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
Study	NNP	study	study	studi	N	O
102	CD	102	102	102	N	O
and	CC	and	and	and	N	O
Study	NNP	study	study	studi	N	O
103	CD	103	103	103	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
infected	JJ	infected	infected	infect	N	O
adult	NN	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
701	CD	701	701	701	N	O
subjects	NNS	subjects	subject	subject	N	O
received	VBN	received	received	receiv	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
once	RB	once	once	onc	N	O
daily	RB	daily	daily	daili	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
two	CD	two	two	two	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
(	(	(	(	(	N	O
elvitegravir	JJ	elvitegravir	elvitegravir	elvitegravir	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
cobicistat	NN	cobicistat	cobicistat	cobicistat	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
emtricitabine	NN	emtricitabine	emtricitabine	emtricitabin	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
(	(	(	(	(	N	O
efavirenz	VBP	efavirenz	efavirenz	efavirenz	N	O
600	CD	600	600	600	N	O
mg	NNS	mg	mg	mg	N	O
emtricitabine	VBP	emtricitabine	emtricitabine	emtricitabin	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
or	CC	or	or	or	N	O
atazanavir	VB	atazanavir	atazanavir	atazanavir	N	O
(	(	(	(	(	N	O
ATV	NNP	atv	atv	atv	N	O
)	)	)	)	)	N	O
ritonavir	NN	ritonavir	ritonavir	ritonavir	N	O
(	(	(	(	(	N	O
RTV	NNP	rtv	rtv	rtv	N	O
)	)	)	)	)	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
(	(	(	(	(	N	O
emtricitabine	JJ	emtricitabine	emtricitabine	emtricitabin	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
)	)	)	)	)	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
severity	NN	severity	severity	sever	N	O
,	,	,	,	,	N	O
was	VBD	was	wa	wa	N	O
6.0%	CD	6.0%	6.0%	6.0%	N	O
,	,	,	,	,	N	O
7.4%	CD	7.4%	7.4%	7.4%	N	O
and	CC	and	and	and	N	O
8.5%	CD	8.5%	8.5%	8.5%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
displays	VBZ	displays	display	display	N	O
the	DT	the	the	the	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
treatment	NN	treatment	treatment	treatment	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Drug	NNP	drug	drug	drug	N	O
ReactionsFrequencies	NNP	reactionsfrequencies	reactionsfrequencies	reactionsfrequ	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
all	DT	all	all	all	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
,	,	,	,	,	N	O
attributed	VBD	attributed	attributed	attribut	N	O
to	TO	to	to	to	N	O
study	VB	study	study	studi	N	O
drugs	NNS	drugs	drug	drug	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
all	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
)	)	)	)	)	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
Subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
Any	NNP	any	any	ani	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Arm	NNP	arm	arm	arm	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
102	CD	102	102	102	N	O
and	CC	and	and	and	N	O
103	CD	103	103	103	N	O
(	(	(	(	(	N	O
Week	JJ	week	week	week	N	O
144	CD	144	144	144	N	O
analysis	NN	analysis	analysis	analysi	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

STRIBILDN	NNP	stribildn	stribildn	stribildn	N	O
701	CD	701	701	701	N	O
ATRIPLAN	NNP	atriplan	atriplan	atriplan	N	O
352	CD	352	352	352	N	O
ATV	NNP	atv	atv	atv	N	O
RTV	NNP	rtv	rtv	rtv	N	O
TRUVADAN	NNP	truvadan	truvadan	truvadan	N	O
355	CD	355	355	355	N	O

EYE	NN	eye	eye	eye	N	O

DISORDERS	NNS	disorders	disorder	disord	N	O

Ocular	JJ	ocular	ocular	ocular	N	B-AdverseReaction
icterus	NN	icterus	icterus	icteru	Y	I-AdverseReaction
1%	CD	1%	1%	1%	N	O
0%	CD	0%	0%	0%	N	O
13%	CD	13%	13%	13%	N	O

GASTROINTESTINAL	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
12%	CD	12%	12%	12%	N	O
11%	CD	11%	11%	11%	N	O
17%	CD	17%	17%	17%	N	O

Flatulence	NN	flatulence	flatulence	flatul	Y	B-AdverseReaction
2%	CD	2%	2%	2%	N	O
1%	CD	1%	1%	1%	N	O
8%	CD	8%	8%	8%	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
16%	CD	16%	16%	16%	N	O
9%	CD	9%	9%	9%	N	O
14%	CD	14%	14%	14%	N	O

GENERAL	NNP	general	general	gener	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O
AND	NNP	and	and	and	N	O
ADMINISTRATION	NNP	administration	administration	administr	N	O
SITE	NNP	site	site	site	N	O
CONDITIONS	NNP	conditions	condition	condit	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
4%	CD	4%	4%	4%	N	O
8%	CD	8%	8%	8%	N	O
6%	CD	6%	6%	6%	N	O

HEPATOBILIARY	NNP	hepatobiliary	hepatobiliary	hepatobiliari	N	O
DISORDERS	NNS	disorders	disorder	disord	N	O

Jaundice	NNP	jaundice	jaundice	jaundic	Y	B-AdverseReaction
0%	CD	0%	0%	0%	N	O
1%	CD	1%	1%	1%	N	O
9%	CD	9%	9%	9%	N	O

NERVOUS	NNP	nervous	nervous	nervou	Y	O
SYSTEM	NNP	system	system	system	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
1%	CD	1%	1%	1%	N	O
7%	CD	7%	7%	7%	N	O
1%	CD	1%	1%	1%	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
7%	CD	7%	7%	7%	N	O
4%	CD	4%	4%	4%	N	O
6%	CD	6%	6%	6%	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
3%	CD	3%	3%	3%	N	O
21%	CD	21%	21%	21%	N	O
5%	CD	5%	5%	5%	N	O

PSYCHIATRIC	NN	psychiatric	psychiatric	psychiatr	N	O
DISORDERS	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
3%	CD	3%	3%	3%	N	O
9%	CD	9%	9%	9%	N	O
1%	CD	1%	1%	1%	N	O

Abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
dreams	VBZ	dreams	dream	dream	N	I-AdverseReaction
9%	CD	9%	9%	9%	N	O
27%	CD	27%	27%	27%	N	O
4%	CD	4%	4%	4%	N	O

SKIN	NNP	skin	skin	skin	N	O
AND	NNP	and	and	and	N	O
SUBCUTANEOUS	NNP	subcutaneous	subcutaneous	subcutan	N	O
TISSUE	NNP	tissue	tissue	tissu	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
4%	CD	4%	4%	4%	N	O
15%	CD	15%	15%	15%	N	O
6%	CD	6%	6%	6%	N	O

See	VB	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
discussion	NN	discussion	discussion	discuss	N	O
of	IN	of	of	of	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
from	IN	from	from	from	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
experience	NN	experience	experience	experi	N	O
with	IN	with	with	with	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
.	.	.	.	.	N	O

Additional	JJ	additional	additional	addit	N	O

adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
observed	VBD	observed	observed	observ	N	O
with	IN	with	with	with	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
included	VBD	included	included	includ	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
ideation	NN	ideation	ideation	ideat	N	I-AdverseReaction
and	CC	and	and	and	N	O
suicide	NN	suicide	suicide	suicid	Y	B-AdverseReaction
attempt	NN	attempt	attempt	attempt	N	I-AdverseReaction
(	(	(	(	(	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
all	DT	all	all	all	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
depression	NN	depression	depression	depress	Y	O
or	CC	or	or	or	N	O
psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
illness	NN	illness	illness	ill	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Virologically	NNP	virologically	virologically	virolog	N	O
-	:	-	-	-	N	O
Suppressed	VBD	suppressed	suppressed	suppress	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
Infected	VBN	infected	infected	infect	N	O
Subjects	NNS	subjects	subject	subject	N	O

No	DT	no	no	no	N	O
new	JJ	new	new	new	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
to	TO	to	to	to	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
through	IN	through	through	through	N	O
Week	NNP	week	week	week	N	O
48	CD	48	48	48	N	O
were	VBD	were	were	were	N	O
identified	VBN	identified	identified	identifi	N	O
in	IN	in	in	in	N	O
584	CD	584	584	584	N	O
virologically	RB	virologically	virologically	virolog	N	O
stably	RB	stably	stably	stabli	N	O
suppressed	JJ	suppressed	suppressed	suppress	N	O
subjects	NNS	subjects	subject	subject	N	O
switching	VBG	switching	switching	switch	N	O
to	TO	to	to	to	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
regimen	NNS	regimen	regimen	regimen	N	O
containing	VBG	containing	containing	contain	N	O
a	DT	a	a	a	N	O
RTV	NNP	rtv	rtv	rtv	N	O
-	:	-	-	-	N	O
boosted	VBD	boosted	boosted	boost	N	O
protease	JJ	protease	protease	proteas	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
(	(	(	(	(	N	O
PI	NNP	pi	pi	pi	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
nucleoside	JJ	nucleoside	nucleoside	nucleosid	N	O
reverse	NN	reverse	reverse	revers	N	O
transcriptase	NN	transcriptase	transcriptase	transcriptas	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
(	(	(	(	(	N	O
NNRTI	NNP	nnrti	nnrti	nnrti	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
combined	JJ	combined	combined	combin	N	O
analysis	NN	analysis	analysis	analysi	N	O
of	IN	of	of	of	N	O
Studies	NNS	studies	study	studi	N	O
115	CD	115	115	115	N	O
and	CC	and	and	and	N	O
121	CD	121	121	121	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
all	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
24%	CD	24%	24%	24%	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
switching	VBG	switching	switching	switch	N	O
to	TO	to	to	to	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
6%	CD	6%	6%	6%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
either	DT	either	either	either	N	O
group	NN	group	group	group	N	O
who	WP	who	who	who	N	O
stayed	VBD	stayed	stayed	stay	N	O
on	IN	on	on	on	N	O
their	PRP$	their	their	their	N	O
baseline	JJ	baseline	baseline	baselin	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
regimen	NNS	regimen	regimen	regimen	N	O
,	,	,	,	,	N	O
RTV	NNP	rtv	rtv	rtv	N	O
-	:	-	-	-	N	O
boosted	VBD	boosted	boosted	boost	N	O
PI	NNP	pi	pi	pi	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
or	CC	or	or	or	N	O
NNRTI	NNP	nnrti	nnrti	nnrti	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
.	.	.	.	.	N	O

Common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
switching	VBG	switching	switching	switch	N	O
to	TO	to	to	to	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
were	VBD	were	were	were	N	O
nausea	RB	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
flatulence	NN	flatulence	flatulence	flatul	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
RTV	NNP	rtv	rtv	rtv	N	O
-	:	-	-	-	N	O
boosted	VBD	boosted	boosted	boost	N	O
PI	NNP	pi	pi	pi	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
NNRTI	NNP	nnrti	nnrti	nnrti	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
,	,	,	,	,	N	O
was	VBD	was	wa	wa	N	O
2%	CD	2%	2%	2%	N	O
,	,	,	,	,	N	O
3%	CD	3%	3%	3%	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
from	IN	from	from	from	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
Components	NNS	components	component	compon	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O

Emtricitabine	NN	emtricitabine	emtricitabine	emtricitabin	N	O
and	CC	and	and	and	N	O
Tenofovir	NNP	tenofovir	tenofovir	tenofovir	N	O
Disoproxil	NNP	disoproxil	disoproxil	disoproxil	N	O
Fumarate	NNP	fumarate	fumarate	fumar	N	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
observed	VBD	observed	observed	observ	N	O
with	IN	with	with	with	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
experienced	VBD	experienced	experienced	experienc	N	O
or	CC	or	or	or	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
emtricitabine	NN	emtricitabine	emtricitabine	emtricitabin	N	O
or	CC	or	or	or	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
agents	NNS	agents	agent	agent	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
:	:	:	:	:	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
dyspepsia	NN	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuritis	NN	neuritis	neuritis	neuriti	Y	I-AdverseReaction
and	CC	and	and	and	N	O
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
cough	NN	cough	cough	cough	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
rhinitis	NN	rhinitis	rhinitis	rhiniti	Y	B-AdverseReaction
.	.	.	.	.	N	O

Skin	NNP	skin	skin	skin	N	B-AdverseReaction
discoloration	NN	discoloration	discoloration	discolor	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
higher	JJR	higher	higher	higher	N	O
frequency	NN	frequency	frequency	frequenc	N	O
among	IN	among	among	among	N	O
emtricitabine	JJ	emtricitabine	emtricitabine	emtricitabin	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
;	:	;	;	;	N	O
it	PRP	it	it	it	N	O
was	VBD	was	wa	wa	N	O
manifested	VBN	manifested	manifested	manifest	N	O
by	IN	by	by	by	N	O
hyperpigmentation	NN	hyperpigmentation	hyperpigmentation	hyperpigment	N	B-AdverseReaction
on	IN	on	on	on	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
palms	NN	palms	palm	palm	N	I-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
soles	NNS	soles	sol	sole	N	I-AdverseReaction
and	CC	and	and	and	N	O
was	VBD	was	wa	wa	N	O
generally	RB	generally	generally	gener	N	O
mild	JJ	mild	mild	mild	N	B-Severity
and	CC	and	and	and	N	O
asymptomatic	JJ	asymptomatic	asymptomatic	asymptomat	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
and	CC	and	and	and	N	O
clinical	JJ	clinical	clinical	clinic	N	O
significance	NN	significance	significance	signific	N	O
are	VBP	are	are	are	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
Abnormalities	NNS	abnormalities	abnormality	abnorm	N	O

The	DT	the	the	the	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
102	CD	102	102	102	N	O
and	CC	and	and	and	N	O
103	CD	103	103	103	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
Subjects	NNS	subjects	subject	subject	N	O
Receiving	VBG	receiving	receiving	receiv	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
102	CD	102	102	102	N	O
and	CC	and	and	and	N	O
103	CD	103	103	103	N	O
(	(	(	(	(	N	O
Week	JJ	week	week	week	N	O
144	CD	144	144	144	N	O
analysis	NN	analysis	analysis	analysi	N	O
)	)	)	)	)	N	O

STRIBILD	NNP	stribild	stribild	stribild	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
ATV	NNP	atv	atv	atv	N	O
RTV	NNP	rtv	rtv	rtv	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O

Parameter	NNP	parameter	parameter	paramet	N	O
Abnormality	NNP	abnormality	abnormality	abnorm	N	O
,	,	,	,	,	N	O
N	NNP	n	n	n	N	O
701	CD	701	701	701	N	O
N	NNP	n	n	n	N	O
352	CD	352	352	352	N	O
N	NNP	n	n	n	N	O
355	CD	355	355	355	N	O

AST	NNP	ast	ast	ast	N	B-AdverseReaction
(	(	(	(	(	N	O
5.0	CD	5.0	5.0	5.0	N	I-AdverseReaction
ULN	NNP	uln	uln	uln	N	I-AdverseReaction
)	)	)	)	)	N	O
3%	CD	3%	3%	3%	N	O
6%	CD	6%	6%	6%	N	O
6%	CD	6%	6%	6%	N	O

ALT	NNP	alt	alt	alt	N	B-AdverseReaction
(	(	(	(	(	N	O
3.0	CD	3.0	3.0	3.0	N	I-AdverseReaction
ULN	NNP	uln	uln	uln	N	I-AdverseReaction
)	)	)	)	)	N	O
2%	CD	2%	2%	2%	N	O
5%	CD	5%	5%	5%	N	O
4%	CD	4%	4%	4%	N	O

Amylase	NNP	amylase	amylase	amylas	Y	B-AdverseReaction
(	(	(	(	(	N	O
2.0	CD	2.0	2.0	2.0	N	I-AdverseReaction
ULN	NNP	uln	uln	uln	N	I-AdverseReaction
)	)	)	)	)	N	O
3%	CD	3%	3%	3%	N	O
3%	CD	3%	3%	3%	N	O
5%	CD	5%	5%	5%	N	O

Creatine	NNP	creatine	creatine	creatin	Y	B-AdverseReaction
Kinase	NNP	kinase	kinase	kinas	N	I-AdverseReaction
(	(	(	(	(	N	O
10.0	CD	10.0	10.0	10.0	N	I-AdverseReaction
ULN	NNP	uln	uln	uln	N	I-AdverseReaction
)	)	)	)	)	N	O
8%	CD	8%	8%	8%	N	O
15%	CD	15%	15%	15%	N	O
11%	CD	11%	11%	11%	N	O

Urine	NNP	urine	urine	urin	N	B-AdverseReaction
RBC	NNP	rbc	rbc	rbc	N	I-AdverseReaction
(	(	(	(	(	N	O
Hematuria	NNP	hematuria	hematuria	hematuria	Y	B-AdverseReaction
)	)	)	)	)	N	O
(	(	(	(	(	N	O
75	CD	75	75	75	N	O
RBC	NNP	rbc	rbc	rbc	N	O
HPF	NNP	hpf	hpf	hpf	N	O
)	)	)	)	)	N	O
4%	CD	4%	4%	4%	N	O
2%	CD	2%	2%	2%	N	O
4%	CD	4%	4%	4%	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
103	CD	103	103	103	N	O
,	,	,	,	,	N	O
BMD	NNP	bmd	bmd	bmd	N	O
was	VBD	was	wa	wa	N	O
assessed	VBN	assessed	assessed	assess	N	O
by	IN	by	by	by	N	O
DEXA	NNP	dexa	dexa	dexa	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
random	NN	random	random	random	N	O
subset	NN	subset	subset	subset	N	O
of	IN	of	of	of	N	O
120	CD	120	120	120	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
group	NN	group	group	group	N	O
N	NNP	n	n	n	N	O
54	CD	54	54	54	N	O
;	:	;	;	;	N	O
ATV	NNP	atv	atv	atv	N	O
RTV	NNP	rtv	rtv	rtv	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
group	NN	group	group	group	N	O
N	NNP	n	n	n	N	O
66	CD	66	66	66	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Mean	JJ	mean	mean	mean	N	O
percentage	NN	percentage	percentage	percentag	N	O
decreases	NNS	decreases	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
BMD	NNP	bmd	bmd	bmd	N	I-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
to	TO	to	to	to	N	O
Week	VB	week	week	week	N	O
144	CD	144	144	144	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
group	NN	group	group	group	N	O
were	VBD	were	were	were	N	O
comparable	JJ	comparable	comparable	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
ATV	NNP	atv	atv	atv	N	O
RTV	NNP	rtv	rtv	rtv	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
group	NN	group	group	group	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
lumbar	NN	lumbar	lumbar	lumbar	N	O
spine	NN	spine	spine	spine	N	O
(-	JJ	(-	(-	(-	N	O
1.43%	CD	1.43%	1.43%	1.43%	N	O
versus	NN	versus	versus	versu	N	O
-	:	-	-	-	N	O
3.68%	CD	3.68%	3.68%	3.68%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
hip	NN	hip	hip	hip	N	O
(-	JJ	(-	(-	(-	N	O
2.83%	CD	2.83%	2.83%	2.83%	N	O
versus	NN	versus	versus	versu	N	O
-	:	-	-	-	N	O
3.77%	CD	3.77%	3.77%	3.77%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
102	CD	102	102	102	N	O
and	CC	and	and	and	N	O
103	CD	103	103	103	N	O
,	,	,	,	,	N	O
bone	NN	bone	bone	bone	N	B-AdverseReaction
fractures	NNS	fractures	fracture	fractur	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
27	CD	27	27	27	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
3.9%	CD	3.9%	3.9%	3.9%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
8	CD	8	8	8	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
19	CD	19	19	19	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
5.4%	CD	5.4%	5.4%	5.4%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ATV	NNP	atv	atv	atv	N	O
RTV	NNP	rtv	rtv	rtv	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
findings	NNS	findings	finding	find	N	O
were	VBD	were	were	were	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
an	DT	an	an	an	N	O
earlier	JJR	earlier	earlier	earlier	N	O
144	CD	144	144	144	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
lamivudine	NN	lamivudine	lamivudine	lamivudin	N	O
efavirenz	NN	efavirenz	efavirenz	efavirenz	N	O
.	.	.	.	.	N	O

Proteinuria	NNS	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction

(	(	(	(	(	N	O
all	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
52%	CD	52%	52%	52%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
,	,	,	,	,	N	O
41%	CD	41%	41%	41%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
42%	CD	42%	42%	42%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ATV	NNP	atv	atv	atv	N	O
RTV	NNP	rtv	rtv	rtv	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
cobicistat	JJ	cobicistat	cobicistat	cobicistat	N	O
component	NN	component	component	compon	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
shown	VBN	shown	shown	shown	N	O
to	TO	to	to	to	N	O
increase	VB	increase	increase	increas	N	B-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
decrease	NN	decrease	decrease	decreas	N	B-AdverseReaction
estimated	VBN	estimated	estimated	estim	N	I-AdverseReaction
creatinine	JJ	creatinine	creatinine	creatinin	Y	I-AdverseReaction
clearance	NN	clearance	clearance	clearanc	N	I-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
of	IN	of	of	of	N	O
tubular	JJ	tubular	tubular	tubular	N	O
secretion	NN	secretion	secretion	secret	N	O
of	IN	of	of	of	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
without	IN	without	without	without	N	B-Negation
affecting	VBG	affecting	affecting	affect	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
glomerular	JJ	glomerular	glomerular	glomerular	N	I-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
102	CD	102	102	102	N	O
and	CC	and	and	and	N	O
103	CD	103	103	103	N	O
,	,	,	,	,	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
decreases	NNS	decreases	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
estimated	VBN	estimated	estimated	estim	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
clearance	NN	clearance	clearance	clearanc	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
early	JJ	early	early	earli	N	O
in	IN	in	in	in	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
,	,	,	,	,	N	O
after	IN	after	after	after	N	O
which	WDT	which	which	which	N	O
they	PRP	they	they	they	N	O
stabilized	VBD	stabilized	stabilized	stabil	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
displays	VBZ	displays	display	display	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
serum	NN	serum	serum	serum	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
and	CC	and	and	and	N	O
eGFR	NN	egfr	egfr	egfr	N	O
levels	NNS	levels	level	level	N	O
at	IN	at	at	at	N	O
Week	NNP	week	week	week	N	O
144	CD	144	144	144	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
(	(	(	(	(	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
Change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	O
Serum	NNP	serum	serum	serum	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
and	CC	and	and	and	N	O
eGFR	NN	egfr	egfr	egfr	N	O
and	CC	and	and	and	N	O
Incidence	NNP	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Elevated	NNP	elevated	elevated	elev	N	B-AdverseReaction
Serum	NNP	serum	serum	serum	N	I-AdverseReaction
Creatinine	NNP	creatinine	creatinine	creatinin	Y	I-AdverseReaction
(	(	(	(	(	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
102	CD	102	102	102	N	O
and	CC	and	and	and	N	O
103	CD	103	103	103	N	O
at	IN	at	at	at	N	O
Week	NNP	week	week	week	N	O
144	CD	144	144	144	N	O

STRIBILD	NNP	stribild	stribild	stribild	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
701	CD	701	701	701	N	O
)	)	)	)	)	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
352	CD	352	352	352	N	O
)	)	)	)	)	N	O
ATV	NNP	atv	atv	atv	N	O
RTV	NNP	rtv	rtv	rtv	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
355	CD	355	355	355	N	O
)	)	)	)	)	N	O

Serum	NN	serum	serum	serum	N	O

Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.14	CD	0.14	0.14	0.14	N	O
(	(	(	(	(	N	O
-	:	-	-	-	N	O
0.14	CD	0.14	0.14	0.14	N	O
)	)	)	)	)	N	O
0.01	CD	0.01	0.01	0.01	N	O
(	(	(	(	(	N	O
-	:	-	-	-	N	O
0.12	CD	0.12	0.12	0.12	N	O
)	)	)	)	)	N	O
0.09	CD	0.09	0.09	0.09	N	O
(	(	(	(	(	N	O
-	:	-	-	-	N	O
0.15	CD	0.15	0.15	0.15	N	O
)	)	)	)	)	N	O

eGFR	NN	egfr	egfr	egfr	N	O
by	IN	by	by	by	N	O
Cockcroft	NNP	cockcroft	cockcroft	cockcroft	N	O
-	:	-	-	-	N	O
Gault	NN	gault	gault	gault	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
minute	NN	minute	minute	minut	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
14.0	CD	14.0	14.0	14.0	N	O
(	(	(	(	(	N	O
-	:	-	-	-	N	O
16.6	CD	16.6	16.6	16.6	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
1.9	CD	1.9	1.9	1.9	N	O
(	(	(	(	(	N	O
-	:	-	-	-	N	O
17.9	CD	17.9	17.9	17.9	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
9.8	CD	9.8	9.8	9.8	N	O
(	(	(	(	(	N	O
-	:	-	-	-	N	O
19.4	CD	19.4	19.4	19.4	N	O
)	)	)	)	)	N	O

Subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
Elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Serum	NNP	serum	serum	serum	N	I-AdverseReaction
Creatinine	NNP	creatinine	creatinine	creatinin	Y	I-AdverseReaction
(	(	(	(	(	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
)(	NNP	)(	)(	)(	N	O
)	)	)	)	)	N	O
12	CD	12	12	12	N	O
2	CD	2	2	2	N	O
6	CD	6	6	6	N	O

Emtricitabine	NN	emtricitabine	emtricitabine	emtricitabin	N	O
or	CC	or	or	or	N	O
Tenofovir	NNP	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
observed	VBN	observed	observed	observ	N	O
with	IN	with	with	with	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
previously	RB	previously	previously	previous	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
emtricitabine	NN	emtricitabine	emtricitabine	emtricitabin	N	O
or	CC	or	or	or	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
agents	NNS	agents	agent	agent	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
:	:	:	:	:	N	O
Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
4	CD	4	4	4	N	I-Severity
laboratory	JJ	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
(	(	(	(	(	N	O
M	NNP	m	m	m	N	O
:	:	:	:	:	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
215	CD	215	215	215	N	B-Severity
U	NNP	u	u	u	N	I-Severity
per	IN	per	per	per	N	I-Severity
L	NNP	l	l	l	N	I-Severity
;	:	;	;	;	N	O
F	NNP	f	f	f	N	O
:	:	:	:	:	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
170	CD	170	170	170	N	B-Severity
U	NNP	u	u	u	N	I-Severity
per	IN	per	per	per	N	I-Severity
L	NNP	l	l	l	N	I-Severity
)	)	)	)	)	N	O
,	,	,	,	,	N	O
alkaline	JJ	alkaline	alkaline	alkalin	N	I-AdverseReaction
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	I-AdverseReaction
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
550	CD	550	550	550	N	B-Severity
U	NNP	u	u	u	N	I-Severity
per	IN	per	per	per	N	I-Severity
L	NNP	l	l	l	N	I-Severity
)	)	)	)	)	N	O
,	,	,	,	,	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
2.5	CD	2.5	2.5	2.5	N	B-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
)	)	)	)	)	N	O
,	,	,	,	,	N	O
serum	FW	serum	serum	serum	N	I-AdverseReaction
glucose	FW	glucose	glucose	glucos	Y	I-AdverseReaction
(	(	(	(	(	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
40	CD	40	40	40	N	B-Severity
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
250	CD	250	250	250	N	B-Severity
mg	NNS	mg	mg	mg	N	I-Severity
per	IN	per	per	per	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
)	)	)	)	)	N	O
,	,	,	,	,	N	O
glycosuria	FW	glycosuria	glycosuria	glycosuria	Y	I-AdverseReaction
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	B-Severity
)	)	)	)	)	N	O
,	,	,	,	,	N	O
neutrophils	FW	neutrophils	neutrophil	neutrophil	Y	I-AdverseReaction
(	(	(	(	(	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
750	CD	750	750	750	N	B-Severity
per	IN	per	per	per	N	I-Severity
mm	NN	mm	mm	mm	N	I-Severity
3	CD	3	3	3	N	I-Severity
)	)	)	)	)	N	O
,	,	,	,	,	N	O
fasting	VBG	fasting	fasting	fast	Y	I-AdverseReaction
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	I-AdverseReaction
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
240	CD	240	240	240	N	B-Severity
mg	NNS	mg	mg	mg	N	I-Severity
per	IN	per	per	per	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
fasting	VBG	fasting	fasting	fast	Y	I-AdverseReaction
triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	I-AdverseReaction
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
750	CD	750	750	750	N	B-Severity
mg	NNS	mg	mg	mg	N	I-Severity
per	IN	per	per	per	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Serum	NN	serum	serum	serum	N	O

Lipids	NNS	lipids	lipid	lipid	Y	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
similar	JJ	similar	similar	similar	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
,	,	,	,	,	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
ATV	NNP	atv	atv	atv	N	O
RTV	NNP	rtv	rtv	rtv	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
were	VBD	were	were	were	N	O
on	IN	on	on	on	N	O
lipid	JJ	lipid	lipid	lipid	N	O
lowering	VBG	lowering	lowering	lower	N	O
agents	NNS	agents	agent	agent	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
,	,	,	,	,	N	O
12%	CD	12%	12%	12%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
13%	CD	13%	13%	13%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

While	IN	while	while	while	N	O
receiving	VBG	receiving	receiving	receiv	N	O
study	JJ	study	study	studi	N	O
drug	NN	drug	drug	drug	N	O
through	IN	through	through	through	N	O
Week	NNP	week	week	week	N	O
144	CD	144	144	144	N	O
,	,	,	,	,	N	O
an	DT	an	an	an	N	O
additional	JJ	additional	additional	addit	N	O
11%	CD	11%	11%	11%	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
subjects	NNS	subjects	subject	subject	N	O
were	VBD	were	were	were	N	O
started	VBN	started	started	start	N	O
on	IN	on	on	on	N	O
lipid	JJ	lipid	lipid	lipid	N	O
lowering	VBG	lowering	lowering	lower	N	O
agents	NNS	agents	agent	agent	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
13%	CD	13%	13%	13%	N	O
of	IN	of	of	of	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
and	CC	and	and	and	N	O
12%	CD	12%	12%	12%	N	O
of	IN	of	of	of	N	O
ATV	NNP	atv	atv	atv	N	O
RTV	NNP	rtv	rtv	rtv	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

Changes	NNS	changes	change	chang	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	O
total	JJ	total	total	total	N	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O
,	,	,	,	,	N	O
HDL	NNP	hdl	hdl	hdl	Y	O
-	:	-	-	-	N	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O
,	,	,	,	,	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
Lipid	NNP	lipid	lipid	lipid	N	O
Values	NNP	values	value	valu	N	O
,	,	,	,	,	N	O
Mean	NNP	mean	mean	mean	N	O
Change	NNP	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
at	IN	at	at	at	N	O
Week	NNP	week	week	week	N	O
144	CD	144	144	144	N	O
in	IN	in	in	in	N	O
Subjects	NNS	subjects	subject	subject	N	O
Receiving	VBG	receiving	receiving	receiv	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
or	CC	or	or	or	N	O
Comparator	NNP	comparator	comparator	compar	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
102	CD	102	102	102	N	O
and	CC	and	and	and	N	O
103	CD	103	103	103	N	O

STRIBILDN	NNP	stribildn	stribildn	stribildn	N	O
701	CD	701	701	701	N	O
ATRIPLAN	NNP	atriplan	atriplan	atriplan	N	O
352	CD	352	352	352	N	O
ATV	NNP	atv	atv	atv	N	O
RTV	NNP	rtv	rtv	rtv	N	O
TRUVADAN	NNP	truvadan	truvadan	truvadan	N	O
355	CD	355	355	355	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
Week	NNP	week	week	week	N	O
144	CD	144	144	144	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
Week	NNP	week	week	week	N	O
144	CD	144	144	144	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
Week	NNP	week	week	week	N	O
144	CD	144	144	144	N	O

mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
Change	NNP	change	change	chang	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
Change	NNP	change	change	chang	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
Change	NN	change	change	chang	N	O

Total	JJ	total	total	total	N	O

Cholesterol	NNP	cholesterol	cholesterol	cholesterol	Y	O
(	(	(	(	(	N	O
fasted	VBN	fasted	fasted	fast	N	O
)	)	)	)	)	N	O
166	CD	166	166	166	N	O
[	JJ	[	[	[	N	O
N	NNP	n	n	n	N	O
675	CD	675	675	675	N	O
]	VBD	]	]	]	N	O
17	CD	17	17	17	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
535	CD	535	535	535	N	O
]	VBD	]	]	]	N	O
161	CD	161	161	161	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
343	CD	343	343	343	N	O
]	VBD	]	]	]	N	O
22	CD	22	22	22	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
262	CD	262	262	262	N	O
]	VBD	]	]	]	N	O
168	CD	168	168	168	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
337	CD	337	337	337	N	O
]	VBD	]	]	]	N	O
16	CD	16	16	16	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
243	CD	243	243	243	N	O
]	NN	]	]	]	N	O

HDL	NNP	hdl	hdl	hdl	Y	O
-	:	-	-	-	N	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O
(	(	(	(	(	N	O
fasted	VBN	fasted	fasted	fast	N	O
)	)	)	)	)	N	O
43	CD	43	43	43	N	O
[	JJ	[	[	[	N	O
N	NNP	n	n	n	N	O
675	CD	675	675	675	N	O
]	VBD	]	]	]	N	O
7	CD	7	7	7	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
535	CD	535	535	535	N	O
]	VBD	]	]	]	N	O
43	CD	43	43	43	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
343	CD	343	343	343	N	O
]	VBD	]	]	]	N	O
9	CD	9	9	9	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
262	CD	262	262	262	N	O
]	VBD	]	]	]	N	O
42	CD	42	42	42	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
335	CD	335	335	335	N	O
]	VBD	]	]	]	N	O
7	CD	7	7	7	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
242	CD	242	242	242	N	O
]	NN	]	]	]	N	O

LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O
(	(	(	(	(	N	O
fasted	VBN	fasted	fasted	fast	N	O
)	)	)	)	)	N	O
100	CD	100	100	100	N	O
[	JJ	[	[	[	N	O
N	NNP	n	n	n	N	O
675	CD	675	675	675	N	O
]	VBD	]	]	]	N	O
15	CD	15	15	15	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
535	CD	535	535	535	N	O
]	VBD	]	]	]	N	O
97	CD	97	97	97	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
343	CD	343	343	343	N	O
]	VBD	]	]	]	N	O
19	CD	19	19	19	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
262	CD	262	262	262	N	O
]	VBD	]	]	]	N	O
101	CD	101	101	101	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
337	CD	337	337	337	N	O
]	VBD	]	]	]	N	O
18	CD	18	18	18	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
242	CD	242	242	242	N	O
]	NN	]	]	]	N	O

Triglycerides	NNP	triglycerides	triglyceride	triglycerid	Y	O
(	(	(	(	(	N	O
fasted	VBN	fasted	fasted	fast	N	O
)	)	)	)	)	N	O
122	CD	122	122	122	N	O
[	JJ	[	[	[	N	O
N	NNP	n	n	n	N	O
675	CD	675	675	675	N	O
]	VBD	]	]	]	N	O
12	CD	12	12	12	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
535	CD	535	535	535	N	O
]	VBD	]	]	]	N	O
121	CD	121	121	121	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
343	CD	343	343	343	N	O
]	VBD	]	]	]	N	O
5	CD	5	5	5	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
262	CD	262	262	262	N	O
]	VBD	]	]	]	N	O
132	CD	132	132	132	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
337	CD	337	337	337	N	O
]	VBD	]	]	]	N	O
22	CD	22	22	22	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
242	CD	242	242	242	N	O
]	NN	]	]	]	N	O

6.2	CD	6.2	6.2	6.2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
additional	JJ	additional	additional	addit	N	O
postmarketing	NN	postmarketing	postmarketing	postmarket	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
specific	VBP	specific	specific	specif	N	O
for	IN	for	for	for	N	O
emtricitabine	NN	emtricitabine	emtricitabine	emtricitabin	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
.	.	.	.	.	N	O

Immune	NNP	immune	immune	immun	N	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

allergic	JJ	allergic	allergic	allerg	N	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
Nutrition	NN	nutrition	nutrition	nutrit	N	O
Disorders	NNS	disorders	disorder	disord	N	O

lactic	JJ	lactic	lactic	lactic	N	B-AdverseReaction
acidosis	NN	acidosis	acidosis	acidosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypophosphatemia	NN	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
Thoracic	NNP	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Mediastinal	NNP	mediastinal	mediastinal	mediastin	N	O
Disorders	NNP	disorders	disorder	disord	N	O

dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
amylase	NN	amylase	amylase	amylas	Y	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction

Hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	O
Disorders	NNS	disorders	disorder	disord	N	O

hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
steatosis	NN	steatosis	steatosis	steatosi	N	I-AdverseReaction
,	,	,	,	,	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
liver	NN	liver	liver	liver	N	I-AdverseReaction
enzymes	RB	enzymes	enzyme	enzym	N	I-AdverseReaction
(	(	(	(	(	N	O
most	JJS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
,	,	,	,	,	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
gamma	NNP	gamma	gamma	gamma	N	I-AdverseReaction
GT	NNP	gt	gt	gt	N	I-AdverseReaction
)	)	)	)	)	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

rash	NN	rash	rash	rash	Y	B-AdverseReaction

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

rhabdomyolysis	NN	rhabdomyolysis	rhabdomyolysis	rhabdomyolysi	Y	B-AdverseReaction
,	,	,	,	,	N	O
osteomalacia	NN	osteomalacia	osteomalacia	osteomalacia	Y	B-AdverseReaction
(	(	(	(	(	N	O
manifested	VBN	manifested	manifested	manifest	N	O
as	IN	as	a	as	N	O
bone	NN	bone	bone	bone	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
and	CC	and	and	and	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
contribute	VB	contribute	contribute	contribut	N	O
to	TO	to	to	to	N	O
fractures	NNS	fractures	fracture	fractur	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
myopathy	NN	myopathy	myopathy	myopathi	Y	B-AdverseReaction

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
Urinary	NNP	urinary	urinary	urinari	N	O
Disorders	NNS	disorders	disorder	disord	N	O

acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
tubular	JJ	tubular	tubular	tubular	N	I-AdverseReaction
necrosis	NN	necrosis	necrosis	necrosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
Fanconi	NNP	fanconi	fanconi	fanconi	N	B-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
proximal	JJ	proximal	proximal	proxim	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
tubulopathy	NN	tubulopathy	tubulopathy	tubulopathi	N	I-AdverseReaction
,	,	,	,	,	N	O
interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
nephritis	NN	nephritis	nephritis	nephriti	Y	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
acute	NN	acute	acute	acut	N	I-AdverseReaction
cases	NNS	cases	case	case	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
nephrogenic	JJ	nephrogenic	nephrogenic	nephrogen	N	B-AdverseReaction
diabetes	NNS	diabetes	diabetes	diabet	Y	I-AdverseReaction
insipidus	VBP	insipidus	insipidus	insipidu	N	I-AdverseReaction
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
insufficiency	NN	insufficiency	insufficiency	insuffici	N	I-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
,	,	,	,	,	N	O
proteinuria	NN	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
polyuria	NN	polyuria	polyuria	polyuria	Y	B-AdverseReaction

General	NNP	general	general	gener	N	O
Disorders	NNP	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
Site	NNP	site	site	site	N	O
Conditions	NNS	conditions	condition	condit	N	O

asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
listed	VBN	listed	listed	list	N	O
under	IN	under	under	under	N	O
the	DT	the	the	the	N	O
body	NN	body	body	bodi	N	O
system	NN	system	system	system	N	O
headings	NNS	headings	heading	head	N	O
above	IN	above	above	abov	N	O
,	,	,	,	,	N	O
may	MD	may	may	may	N	O
occur	VB	occur	occur	occur	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
consequence	NN	consequence	consequence	consequ	N	O
of	IN	of	of	of	N	O
proximal	JJ	proximal	proximal	proxim	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
tubulopathy	NN	tubulopathy	tubulopathy	tubulopathi	N	I-AdverseReaction
:	:	:	:	:	N	O
rhabdomyolysis	NN	rhabdomyolysis	rhabdomyolysis	rhabdomyolysi	Y	B-AdverseReaction
,	,	,	,	,	N	O
osteomalacia	NN	osteomalacia	osteomalacia	osteomalacia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
myopathy	NN	myopathy	myopathy	myopathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypophosphatemia	NN	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
LACTIC	JJ	lactic	lactic	lactic	N	B-AdverseReaction
ACIDOSIS	NNP	acidosis	acidosis	acidosi	Y	I-AdverseReaction
SEVERE	NNP	severe	severe	sever	N	B-Severity
HEPATOMEGALY	NNP	hepatomegaly	hepatomegaly	hepatomegali	Y	B-AdverseReaction
WITH	NNP	with	with	with	N	O
STEATOSIS	NNP	steatosis	steatosis	steatosi	N	B-AdverseReaction
and	CC	and	and	and	N	O
POST	NNP	post	post	post	N	O
TREATMENT	NNP	treatment	treatment	treatment	N	O
ACUTE	NNP	acute	acute	acut	N	B-AdverseReaction
EXACERBATION	NNP	exacerbation	exacerbation	exacerb	N	I-AdverseReaction
OF	NNP	of	of	of	N	I-AdverseReaction
HEPATITIS	NNP	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
B	NNP	b	b	b	N	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
LACTIC	JJ	lactic	lactic	lactic	N	B-AdverseReaction
ACIDOSIS	NNP	acidosis	acidosis	acidosi	Y	I-AdverseReaction
SEVERE	NNP	severe	severe	sever	N	B-Severity
HEPATOMEGALY	NNP	hepatomegaly	hepatomegaly	hepatomegali	Y	B-AdverseReaction
WITH	NNP	with	with	with	N	O
STEATOSIS	NNP	steatosis	steatosis	steatosi	N	B-AdverseReaction
and	CC	and	and	and	N	O
POST	NNP	post	post	post	N	O
TREATMENT	NNP	treatment	treatment	treatment	N	O
ACUTE	NNP	acute	acute	acut	N	B-AdverseReaction
EXACERBATION	NNP	exacerbation	exacerbation	exacerb	N	I-AdverseReaction
OF	NNP	of	of	of	N	I-AdverseReaction
HEPATITIS	NNP	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
B	NNP	b	b	b	N	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Lactic	NNP	lactic	lactic	lactic	N	B-AdverseReaction
acidosis	NN	acidosis	acidosis	acidosi	Y	I-AdverseReaction
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	B-Severity
hepatomegaly	NN	hepatomegaly	hepatomegaly	hepatomegali	Y	B-AdverseReaction
with	IN	with	with	with	N	O
steatosis	NN	steatosis	steatosis	steatosi	N	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
nucleoside	JJ	nucleoside	nucleoside	nucleosid	N	O
analogs	NNS	analogs	analog	analog	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
tenofovir	JJ	tenofovir	tenofovir	tenofovir	N	O
disoproxil	NN	disoproxil	disoproxil	disoproxil	N	O
fumarate	NN	fumarate	fumarate	fumar	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
component	NN	component	component	compon	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
antiretrovirals	NNS	antiretrovirals	antiretrovirals	antiretrovir	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

STRIBILD	NNP	stribild	stribild	stribild	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
approved	VBN	approved	approved	approv	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
chronic	JJ	chronic	chronic	chronic	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
virus	NN	virus	virus	viru	N	O
(	(	(	(	(	N	O
HBV	NNP	hbv	hbv	hbv	N	O
)	)	)	)	)	N	O
infection	NN	infection	infection	infect	Y	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
and	CC	and	and	and	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
coinfected	VBN	coinfected	coinfected	coinfect	N	O
with	IN	with	with	with	N	O
HBV	NNP	hbv	hbv	hbv	N	O
and	CC	and	and	and	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Severe	NNP	severe	severe	sever	N	B-Severity
acute	JJ	acute	acute	acut	N	B-AdverseReaction
exacerbations	NNS	exacerbations	exacerbation	exacerb	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
hepatitis	NN	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
B	NNP	b	b	b	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
coinfected	VBN	coinfected	coinfected	coinfect	N	O
with	IN	with	with	with	N	O
HBV	NNP	hbv	hbv	hbv	N	O
and	CC	and	and	and	N	O
human	JJ	human	human	human	N	O
immunodeficiency	NN	immunodeficiency	immunodeficiency	immunodefici	Y	O
virus	NN	virus	virus	viru	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
have	VBP	have	have	have	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
EMTRIVA	NNP	emtriva	emtriva	emtriva	N	O
or	CC	or	or	or	N	O
VIREAD	NNP	viread	viread	viread	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
are	VBP	are	are	are	N	O
components	NNS	components	component	compon	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
.	.	.	.	.	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	O
function	NN	function	function	function	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
closely	RB	closely	closely	close	N	O
with	IN	with	with	with	N	O
both	DT	both	both	both	N	O
clinical	JJ	clinical	clinical	clinic	N	O
and	CC	and	and	and	N	O
laboratory	JJ	laboratory	laboratory	laboratori	N	O
follow	NN	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	RB	up	up	up	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
several	JJ	several	several	sever	N	O
months	NNS	months	month	month	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
coinfected	VBN	coinfected	coinfected	coinfect	N	O
with	IN	with	with	with	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
HBV	NNP	hbv	hbv	hbv	N	O
and	CC	and	and	and	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
,	,	,	,	,	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
therapy	NN	therapy	therapy	therapi	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
warranted	VBN	warranted	warranted	warrant	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
LACTIC	JJ	lactic	lactic	lactic	N	B-AdverseReaction
ACIDOSIS	NNP	acidosis	acidosis	acidosi	Y	I-AdverseReaction
SEVERE	NNP	severe	severe	sever	N	B-Severity
HEPATOMEGALY	NNP	hepatomegaly	hepatomegaly	hepatomegali	Y	B-AdverseReaction
WITH	NNP	with	with	with	N	O
STEATOSIS	NNP	steatosis	steatosis	steatosi	N	B-AdverseReaction
and	CC	and	and	and	N	O
POST	NNP	post	post	post	N	O
TREATMENT	NNP	treatment	treatment	treatment	N	O
ACUTE	NNP	acute	acute	acut	N	B-AdverseReaction
EXACERBATION	NNP	exacerbation	exacerbation	exacerb	N	I-AdverseReaction
OF	NNP	of	of	of	N	I-AdverseReaction
HEPATITIS	NNP	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
B	NNP	b	b	b	N	I-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Lactic	JJ	lactic	lactic	lactic	N	B-AdverseReaction
acidosis	NN	acidosis	acidosis	acidosi	Y	I-AdverseReaction
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	B-Severity
hepatomegaly	NN	hepatomegaly	hepatomegaly	hepatomegali	Y	B-AdverseReaction
with	IN	with	with	with	N	O
steatosis	NN	steatosis	steatosis	steatosi	N	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
nucleoside	JJ	nucleoside	nucleoside	nucleosid	N	O
analogs	NNS	analogs	analog	analog	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
tenofovir	JJ	tenofovir	tenofovir	tenofovir	N	O
disoproxil	NN	disoproxil	disoproxil	disoproxil	N	O
fumarate	NN	fumarate	fumarate	fumar	N	O
(	(	(	(	(	N	O
DF	NNP	df	df	df	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
component	NN	component	component	compon	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	FW	\n	\n	\n	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
approved	VBN	approved	approved	approv	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
chronic	JJ	chronic	chronic	chronic	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
virus	NN	virus	virus	viru	N	O
(	(	(	(	(	N	O
HBV	NNP	hbv	hbv	hbv	N	O
)	)	)	)	)	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Severe	NNP	severe	severe	sever	N	B-Severity
acute	JJ	acute	acute	acut	N	B-AdverseReaction
exacerbations	NNS	exacerbations	exacerbation	exacerb	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
hepatitis	NN	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
B	NNP	b	b	b	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
coinfected	VBN	coinfected	coinfected	coinfect	N	O
with	IN	with	with	with	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
HBV	NNP	hbv	hbv	hbv	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
EMTRIVA	NNP	emtriva	emtriva	emtriva	N	O
or	CC	or	or	or	N	O
VIREAD	NNP	viread	viread	viread	N	O
,	,	,	,	,	N	O
two	CD	two	two	two	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
components	NNS	components	component	compon	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
.	.	.	.	.	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	O
function	NN	function	function	function	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
closely	RB	closely	closely	close	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
,	,	,	,	,	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
therapy	NN	therapy	therapy	therapi	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
warranted	VBN	warranted	warranted	warrant	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
New	NNP	new	new	new	N	B-AdverseReaction
onset	MD	onset	onset	onset	N	I-AdverseReaction
or	CC	or	or	or	N	O
worsening	VBG	worsening	worsening	worsen	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
:	:	:	:	:	N	O
Can	MD	can	can	can	N	B-Factor
include	VB	include	include	includ	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
and	CC	and	and	and	N	O
Fanconi	NNP	fanconi	fanconi	fanconi	N	B-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
.	.	.	.	.	N	O

Assess	NNP	assess	ass	assess	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
(	(	(	(	(	N	O
CLcr	NNP	clcr	clcr	clcr	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
urine	JJ	urine	urine	urin	N	O
glucose	NN	glucose	glucose	glucos	Y	O
and	CC	and	and	and	N	O
urine	JJ	urine	urine	urin	N	O
protein	NN	protein	protein	protein	Y	O
before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
CLcr	NNP	clcr	clcr	clcr	N	O
,	,	,	,	,	N	O
urine	JJ	urine	urine	urin	N	O
glucose	NN	glucose	glucose	glucos	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urine	JJ	urine	urine	urin	N	O
protein	NN	protein	protein	protein	Y	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
serum	NN	serum	serum	serum	N	O
phosphorus	NN	phosphorus	phosphorus	phosphoru	Y	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
.	.	.	.	.	N	O

Avoid	NNP	avoid	avoid	avoid	N	O
administering	VBG	administering	administering	administ	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
with	IN	with	with	with	N	O
concurrent	NN	concurrent	concurrent	concurr	N	O
or	CC	or	or	or	N	O
recent	JJ	recent	recent	recent	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
nephrotoxic	JJ	nephrotoxic	nephrotoxic	nephrotox	N	O
drugs	NNS	drugs	drug	drug	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Avoid	NNP	avoid	avoid	avoid	N	O
coadministration	NN	coadministration	coadministration	coadministr	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
retroviral	JJ	retroviral	retroviral	retrovir	N	O
products	NNS	products	product	product	N	O
:	:	:	:	:	N	O
Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
with	IN	with	with	with	N	O
products	NNS	products	product	product	N	O
containing	VBG	containing	containing	contain	N	O
any	DT	any	any	ani	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
components	NNS	components	component	compon	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
(	(	(	(	(	N	O
cobicistat	NN	cobicistat	cobicistat	cobicistat	N	O
,	,	,	,	,	N	O
elvitegravir	NN	elvitegravir	elvitegravir	elvitegravir	N	O
,	,	,	,	,	N	O
emtricitabine	NN	emtricitabine	emtricitabine	emtricitabin	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
tenofovir	JJ	tenofovir	tenofovir	tenofovir	N	O
disoproxil	NN	disoproxil	disoproxil	disoproxil	N	O
fumarate	NN	fumarate	fumarate	fumar	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
,	,	,	,	,	N	O
COMPLERA	NNP	complera	complera	complera	N	O
,	,	,	,	,	N	O
EMTRIVA	NNP	emtriva	emtriva	emtriva	N	O
,	,	,	,	,	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
,	,	,	,	,	N	O
TYBOST	NNP	tybost	tybost	tybost	N	O
,	,	,	,	,	N	O
VIREAD	NNP	viread	viread	viread	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
VITEKTA	NNP	vitekta	vitekta	vitekta	N	O
;	:	;	;	;	N	O
with	IN	with	with	with	N	O
drugs	NNS	drugs	drug	drug	N	O
containing	VBG	containing	containing	contain	N	O
lamivudine	NN	lamivudine	lamivudine	lamivudin	N	O
;	:	;	;	;	N	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
drugs	NNS	drugs	drug	drug	N	O
or	CC	or	or	or	N	O
regimens	NNS	regimens	regimen	regimen	N	O
containing	VBG	containing	containing	contain	N	O
ritonavir	NN	ritonavir	ritonavir	ritonavir	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
administer	VB	administer	administer	administ	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
HEPSERA	NNP	hepsera	hepsera	hepsera	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
or	CC	or	or	or	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
virologic	JJ	virologic	virologic	virolog	N	O
response	NN	response	response	respons	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
interactions	NNS	interactions	interaction	interact	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
concomitant	NN	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
may	MD	may	may	may	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
known	NN	known	known	known	N	O
or	CC	or	or	or	N	O
potentially	RB	potentially	potentially	potenti	N	O
significant	JJ	significant	significant	signific	N	O
drug	NN	drug	drug	drug	N	O
interactions	NNS	interactions	interaction	interact	N	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
and	CC	and	and	and	N	O
possible	JJ	possible	possible	possibl	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
resistance	NN	resistance	resistance	resist	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
possible	JJ	possible	possible	possibl	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
from	IN	from	from	from	N	O
greater	JJR	greater	greater	greater	N	O
exposures	NNS	exposures	exposure	exposur	N	O
of	IN	of	of	of	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
drugs	NNS	drugs	drug	drug	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Decreases	NNS	decreases	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
bone	JJ	bone	bone	bone	N	I-AdverseReaction
mineral	JJ	mineral	mineral	miner	N	I-AdverseReaction
density	NN	density	density	densiti	N	I-AdverseReaction
(	(	(	(	(	N	O
BMD	NNP	bmd	bmd	bmd	N	I-AdverseReaction
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Consider	VB	consider	consider	consid	N	O
monitoring	VBG	monitoring	monitoring	monitor	N	O
BMD	NNP	bmd	bmd	bmd	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
pathologic	JJ	pathologic	pathologic	patholog	N	O
fracture	NN	fracture	fracture	fractur	Y	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
of	IN	of	of	of	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
or	CC	or	or	or	N	O
bone	NN	bone	bone	bone	N	O
loss	NN	loss	loss	loss	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Redistribution	NNP	redistribution	redistribution	redistribut	N	B-AdverseReaction
accumulation	NN	accumulation	accumulation	accumul	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
fat	NN	fat	fat	fat	N	I-AdverseReaction
:	:	:	:	:	N	O
Observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
reconstitution	NN	reconstitution	reconstitution	reconstitut	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
:	:	:	:	:	N	O
May	NNP	may	may	may	N	O
necessitate	VB	necessitate	necessitate	necessit	N	O
further	JJ	further	further	further	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Lactic	JJ	lactic	lactic	lactic	N	O

Acidosis	NNP	acidosis	acidosis	acidosi	Y	O
Severe	NNP	severe	severe	sever	N	O
Hepatomegaly	NNP	hepatomegaly	hepatomegaly	hepatomegali	Y	O
with	IN	with	with	with	N	O
Steatosis	NNP	steatosis	steatosis	steatosi	N	O

Lactic	JJ	lactic	lactic	lactic	N	B-AdverseReaction
acidosis	NN	acidosis	acidosis	acidosi	Y	I-AdverseReaction
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	B-Severity
hepatomegaly	NN	hepatomegaly	hepatomegaly	hepatomegali	Y	B-AdverseReaction
with	IN	with	with	with	N	O
steatosis	NN	steatosis	steatosis	steatosi	N	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
nucleoside	JJ	nucleoside	nucleoside	nucleosid	N	O
analogs	NNS	analogs	analog	analog	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
component	NN	component	component	compon	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
antiretrovirals	NNS	antiretrovirals	antiretrovirals	antiretrovir	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
cases	NNS	cases	case	case	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
.	.	.	.	.	N	O

Obesity	NN	obesity	obesity	obes	Y	O
and	CC	and	and	and	N	O
prolonged	JJ	prolonged	prolonged	prolong	N	O
nucleoside	NN	nucleoside	nucleoside	nucleosid	N	O
exposure	NN	exposure	exposure	exposur	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
risk	JJ	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
.	.	.	.	.	N	O

Particular	JJ	particular	particular	particular	N	O
caution	NN	caution	caution	caution	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
exercised	VBN	exercised	exercised	exercis	N	O
when	WRB	when	when	when	N	O
administering	VBG	administering	administering	administ	N	O
nucleoside	RB	nucleoside	nucleoside	nucleosid	N	O
analogs	NNS	analogs	analog	analog	N	O
to	TO	to	to	to	N	O
any	DT	any	any	ani	N	O
patient	NN	patient	patient	patient	N	O
with	IN	with	with	with	N	O
known	VBN	known	known	known	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
liver	JJ	liver	liver	liver	N	O
disease	NN	disease	disease	diseas	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
cases	NNS	cases	case	case	N	O
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
no	DT	no	no	no	N	O
known	VBN	known	known	known	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
suspended	VBN	suspended	suspended	suspend	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
patient	NN	patient	patient	patient	N	O
who	WP	who	who	who	N	O
develops	VBZ	develops	develops	develop	N	O
clinical	JJ	clinical	clinical	clinic	N	O
or	CC	or	or	or	N	O
laboratory	JJ	laboratory	laboratory	laboratori	N	O
findings	NNS	findings	finding	find	N	O
suggestive	NN	suggestive	suggestive	suggest	N	O
of	IN	of	of	of	N	O
lactic	JJ	lactic	lactic	lactic	N	O
acidosis	NN	acidosis	acidosis	acidosi	Y	O
or	CC	or	or	or	N	O
pronounced	VBN	pronounced	pronounced	pronounc	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O
(	(	(	(	(	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
include	VB	include	include	includ	N	O
hepatomegaly	NN	hepatomegaly	hepatomegaly	hepatomegali	Y	O
and	CC	and	and	and	N	O
steatosis	NN	steatosis	steatosis	steatosi	N	O
even	RB	even	even	even	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	O
of	IN	of	of	of	N	O
marked	JJ	marked	marked	mark	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	O
elevations	NNS	elevations	elevation	elev	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Patients	NNS	patients	patient	patient	N	O
Coinfected	VBN	coinfected	coinfected	coinfect	N	O
with	IN	with	with	with	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
HBV	NNP	hbv	hbv	hbv	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
that	IN	that	that	that	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
be	VB	be	be	be	N	O
tested	VBN	tested	tested	test	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
chronic	JJ	chronic	chronic	chronic	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
virus	NN	virus	virus	viru	N	O
(	(	(	(	(	N	O
HBV	NNP	hbv	hbv	hbv	N	O
)	)	)	)	)	N	O
before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

STRIBILD	NNP	stribild	stribild	stribild	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
approved	VBN	approved	approved	approv	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
chronic	JJ	chronic	chronic	chronic	N	O
HBV	NNP	hbv	hbv	hbv	N	O
infection	NN	infection	infection	infect	Y	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
and	CC	and	and	and	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
coinfected	VBN	coinfected	coinfected	coinfect	N	O
with	IN	with	with	with	N	O
HBV	NNP	hbv	hbv	hbv	N	O
and	CC	and	and	and	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Severe	NNP	severe	severe	sever	N	O
acute	JJ	acute	acute	acut	N	O
exacerbations	NNS	exacerbations	exacerbation	exacerb	N	O
of	IN	of	of	of	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
coinfected	VBN	coinfected	coinfected	coinfect	N	O
with	IN	with	with	with	N	O
HBV	NNP	hbv	hbv	hbv	N	O
and	CC	and	and	and	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
have	VBP	have	have	have	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
emtricitabine	NN	emtricitabine	emtricitabine	emtricitabin	N	O
or	CC	or	or	or	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
,	,	,	,	,	N	O
two	CD	two	two	two	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
components	NNS	components	component	compon	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
infected	VBN	infected	infected	infect	N	O
with	IN	with	with	with	N	O
HBV	NNP	hbv	hbv	hbv	N	O
and	CC	and	and	and	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
EMTRIVA	NNP	emtriva	emtriva	emtriva	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
exacerbations	NNS	exacerbations	exacerbation	exacerb	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
hepatitis	NN	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
B	NNP	b	b	b	N	I-AdverseReaction
were	VBD	were	were	were	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
liver	JJ	liver	liver	liver	N	B-AdverseReaction
decompensation	NN	decompensation	decompensation	decompens	N	I-AdverseReaction
and	CC	and	and	and	N	O
liver	JJ	liver	liver	liver	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
coinfected	VBN	coinfected	coinfected	coinfect	N	O
with	IN	with	with	with	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
HBV	NNP	hbv	hbv	hbv	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
closely	RB	closely	closely	close	N	O
monitored	VBN	monitored	monitored	monitor	N	O
with	IN	with	with	with	N	O
both	DT	both	both	both	N	O
clinical	JJ	clinical	clinical	clinic	N	O
and	CC	and	and	and	N	O
laboratory	JJ	laboratory	laboratory	laboratori	N	O
follow	NN	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	RB	up	up	up	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
several	JJ	several	several	sever	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
stopping	VBG	stopping	stopping	stop	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
,	,	,	,	,	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
therapy	NN	therapy	therapy	therapi	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
warranted	VBN	warranted	warranted	warrant	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
New	NNP	new	new	new	N	O
Onset	NNP	onset	onset	onset	N	O
or	CC	or	or	or	N	O
Worsening	NNP	worsening	worsening	worsen	N	O
Renal	NNP	renal	renal	renal	N	O
Impairment	NNP	impairment	impairment	impair	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
and	CC	and	and	and	N	O
Fanconi	NNP	fanconi	fanconi	fanconi	N	B-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
tubular	JJ	tubular	tubular	tubular	N	I-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	B-Severity
hypophosphatemia	NN	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
component	NN	component	component	compon	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
over	IN	over	over	over	N	O
144	CD	144	144	144	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
1.9%	CD	1.9%	1.9%	1.9%	N	O
)	)	)	)	)	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
group	NN	group	group	group	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
701	CD	701	701	701	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
)	)	)	)	)	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ATV	NNP	atv	atv	atv	N	O
RTV	NNP	rtv	rtv	rtv	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
group	NN	group	group	group	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
355	CD	355	355	355	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
no	DT	no	no	no	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
group	NN	group	group	group	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
352	CD	352	352	352	N	O
)	)	)	)	)	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
study	JJ	study	study	studi	N	O
drug	NN	drug	drug	drug	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
discontinuations	NNS	discontinuations	discontinuation	discontinu	N	O
,	,	,	,	,	N	O
8	CD	8	8	8	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ATV	NNP	atv	atv	atv	N	O
RTV	NNP	rtv	rtv	rtv	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
group	NN	group	group	group	N	O
occurred	VBD	occurred	occurred	occur	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
48	CD	48	48	48	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

Four	CD	four	four	four	N	O
(	(	(	(	(	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
)	)	)	)	)	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
developed	VBD	developed	developed	develop	N	O
laboratory	JJ	laboratory	laboratory	laboratori	N	O
findings	NNS	findings	finding	find	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
proximal	JJ	proximal	proximal	proxim	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
tubular	NN	tubular	tubular	tubular	N	I-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
48	CD	48	48	48	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
four	CD	four	four	four	N	O
subjects	NNS	subjects	subject	subject	N	O
had	VBD	had	had	had	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
(	(	(	(	(	N	O
i	JJ	i	i	i	N	O
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O

estimated	VBN	estimated	estimated	estim	N	O
creatinine	JJ	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
70	CD	70	70	70	N	O
mL	NNS	ml	ml	ml	N	O
per	IN	per	per	per	N	O
minute	NN	minute	minute	minut	N	O
)	)	)	)	)	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
findings	NNS	findings	finding	find	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
4	CD	4	4	4	N	O
subjects	NNS	subjects	subject	subject	N	O
improved	VBN	improved	improved	improv	N	O
but	CC	but	but	but	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
completely	RB	completely	completely	complet	N	O
resolve	VB	resolve	resolve	resolv	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
subjects	NNS	subjects	subject	subject	N	O
upon	IN	upon	upon	upon	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
.	.	.	.	.	N	O

Renal	JJ	renal	renal	renal	N	O
replacement	NN	replacement	replacement	replac	N	O
therapy	NN	therapy	therapy	therapi	N	O
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	O
required	VBN	required	required	requir	N	O
for	IN	for	for	for	N	O
these	DT	these	these	these	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
(	(	(	(	(	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
)	)	)	)	)	N	O
subject	NN	subject	subject	subject	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
ATV	NNP	atv	atv	atv	N	O
RTV	NNP	rtv	rtv	rtv	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
developed	VBD	developed	developed	develop	N	O
laboratory	JJ	laboratory	laboratory	laboratori	N	O
findings	NNS	findings	finding	find	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
proximal	JJ	proximal	proximal	proxim	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
tubular	NN	tubular	tubular	tubular	N	I-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
ATV	NNP	atv	atv	atv	N	O
RTV	NNP	rtv	rtv	rtv	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
after	IN	after	after	after	N	O
Week	NNP	week	week	week	N	O
96	CD	96	96	96	N	O
.	.	.	.	.	N	O

STRIBILD	NNP	stribild	stribild	stribild	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
avoided	VBN	avoided	avoided	avoid	N	O
with	IN	with	with	with	N	O
concurrent	NN	concurrent	concurrent	concurr	N	O
or	CC	or	or	or	N	O
recent	JJ	recent	recent	recent	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
nephrotoxic	JJ	nephrotoxic	nephrotoxic	nephrotox	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
high	JJ	high	high	high	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
or	CC	or	or	or	N	O
multiple	JJ	multiple	multiple	multipl	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
steroidal	NN	steroidal	steroidal	steroid	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
inflammatory	NN	inflammatory	inflammatory	inflammatori	N	O
drugs	NNS	drugs	drug	drug	N	O
(	(	(	(	(	N	O
NSAIDs	NNP	nsaids	nsaid	nsaid	N	O
))	NNP	))	))	))	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.4	CD	7.4	7.4	7.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
acute	JJ	acute	acute	acut	N	O
renal	JJ	renal	renal	renal	N	O
failure	NN	failure	failure	failur	N	O
after	IN	after	after	after	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
high	JJ	high	high	high	N	O
dose	NN	dose	dose	dose	N	O
or	CC	or	or	or	N	O
multiple	JJ	multiple	multiple	multipl	N	O
NSAIDs	NNP	nsaids	nsaid	nsaid	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
infected	VBD	infected	infected	infect	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
renal	JJ	renal	renal	renal	N	O
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	O
who	WP	who	who	who	N	O
appeared	VBD	appeared	appeared	appear	N	O
stable	JJ	stable	stable	stabl	N	O
on	IN	on	on	on	N	O
tenofovir	JJ	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
required	VBN	required	required	requir	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
and	CC	and	and	and	N	O
renal	JJ	renal	renal	renal	N	O
replacement	NN	replacement	replacement	replac	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Alternatives	NNS	alternatives	alternative	altern	N	O
to	TO	to	to	to	N	O
NSAIDs	NNP	nsaids	nsaid	nsaid	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
,	,	,	,	,	N	O
if	IN	if	if	if	N	O
needed	VBN	needed	needed	need	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
renal	JJ	renal	renal	renal	N	O
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	O
.	.	.	.	.	N	O

Persistent	NN	persistent	persistent	persist	N	O
or	CC	or	or	or	N	O
worsening	VBG	worsening	worsening	worsen	N	O
bone	NN	bone	bone	bone	N	O
pain	NN	pain	pain	pain	Y	O
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	O
in	IN	in	in	in	N	O
extremities	NNS	extremities	extremity	extrem	N	O
,	,	,	,	,	N	O
fractures	NNS	fractures	fracture	fractur	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
muscular	JJ	muscular	muscular	muscular	N	O
pain	NN	pain	pain	pain	Y	O
or	CC	or	or	or	N	O
weakness	NN	weakness	weakness	weak	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
manifestations	NNS	manifestations	manifestation	manifest	N	O
of	IN	of	of	of	N	O
proximal	JJ	proximal	proximal	proxim	N	O
renal	JJ	renal	renal	renal	N	O
tubulopathy	NN	tubulopathy	tubulopathy	tubulopathi	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
prompt	VB	prompt	prompt	prompt	N	O
an	DT	an	an	an	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
-	:	-	-	-	N	O
risk	NN	risk	risk	risk	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Estimated	VBN	estimated	estimated	estim	N	O
creatinine	JJ	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
,	,	,	,	,	N	O
urine	JJ	urine	urine	urin	N	O
glucose	NN	glucose	glucose	glucos	Y	O
and	CC	and	and	and	N	O
urine	JJ	urine	urine	urin	N	O
protein	NN	protein	protein	protein	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
documented	VBN	documented	documented	document	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
estimated	VBN	estimated	estimated	estim	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
below	IN	below	below	below	N	O
70	CD	70	70	70	N	O
mL	NNS	ml	ml	ml	N	O
per	IN	per	per	per	N	O
minute	NN	minute	minute	minut	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

Routine	JJ	routine	routine	routin	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
estimated	VBN	estimated	estimated	estim	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
,	,	,	,	,	N	O
urine	JJ	urine	urine	urin	N	O
glucose	NN	glucose	glucose	glucos	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urine	JJ	urine	urine	urin	N	O
protein	NN	protein	protein	protein	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
performed	VBN	performed	performed	perform	N	O
during	IN	during	during	dure	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Additionally	RB	additionally	additionally	addit	N	O
,	,	,	,	,	N	O
serum	JJ	serum	serum	serum	N	O
phosphorus	NN	phosphorus	phosphorus	phosphoru	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
measured	VBN	measured	measured	measur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
.	.	.	.	.	N	O

Although	IN	although	although	although	N	O
cobicistat	NN	cobicistat	cobicistat	cobicistat	N	O
(	(	(	(	(	N	O
a	DT	a	a	a	N	O
component	NN	component	component	compon	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
)	)	)	)	)	N	O
may	MD	may	may	may	N	B-Factor
cause	VB	cause	cause	caus	N	O
modest	JJ	modest	modest	modest	N	B-Severity
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
modest	JJ	modest	modest	modest	N	B-Severity
declines	NNS	declines	decline	declin	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
estimated	VBN	estimated	estimated	estim	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
clearance	NN	clearance	clearance	clearanc	N	I-AdverseReaction
without	IN	without	without	without	N	O
affecting	VBG	affecting	affecting	affect	N	O
renal	JJ	renal	renal	renal	N	O
glomerular	JJ	glomerular	glomerular	glomerular	N	O
function	NN	function	function	function	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experience	VBP	experience	experience	experi	N	O
a	DT	a	a	a	N	O
confirmed	JJ	confirmed	confirmed	confirm	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
serum	JJ	serum	serum	serum	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
of	IN	of	of	of	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
0.4	CD	0.4	0.4	0.4	N	O
mg	NNS	mg	mg	mg	N	O
per	IN	per	per	per	N	O
dL	NN	dl	dl	dl	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
closely	RB	closely	closely	close	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
renal	JJ	renal	renal	renal	N	O
safety	NN	safety	safety	safeti	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
emtricitabine	NN	emtricitabine	emtricitabine	emtricitabin	N	O
and	CC	and	and	and	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
components	NNS	components	component	compon	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
are	VBP	are	are	are	N	O
primarily	RB	primarily	primarily	primarili	N	O
excreted	VBN	excreted	excreted	excret	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
kidney	NN	kidney	kidney	kidney	N	O
.	.	.	.	.	N	O

STRIBILD	NNP	stribild	stribild	stribild	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
if	IN	if	if	if	N	O
estimated	VBN	estimated	estimated	estim	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
declines	NNS	declines	decline	declin	N	O
below	IN	below	below	below	N	O
50	CD	50	50	50	N	O
mL	NNS	ml	ml	ml	N	O
per	IN	per	per	per	N	O
minute	NN	minute	minute	minut	N	O
as	IN	as	a	as	N	O
dose	JJ	dose	dose	dose	N	O
interval	JJ	interval	interval	interv	N	O
adjustment	NN	adjustment	adjustment	adjust	N	O
required	VBN	required	required	requir	N	O
for	IN	for	for	for	N	O
emtricitabine	NN	emtricitabine	emtricitabine	emtricitabin	N	O
and	CC	and	and	and	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
achieved	VBN	achieved	achieved	achiev	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
combination	NN	combination	combination	combin	N	O
tablet	NN	tablet	tablet	tablet	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Avoid	NNP	avoid	avoid	avoid	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Other	JJ	other	other	other	N	O
Antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
Products	NNS	products	product	product	N	O

STRIBILD	NNP	stribild	stribild	stribild	N	O
is	VBZ	is	is	is	N	O
indicated	VBN	indicated	indicated	indic	N	O
for	IN	for	for	for	N	O
use	NN	use	use	use	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
complete	JJ	complete	complete	complet	N	O
regimen	NN	regimen	regimen	regimen	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
infection	NN	infection	infection	infect	Y	O
and	CC	and	and	and	N	O
coadministration	NN	coadministration	coadministration	coadministr	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
products	NNS	products	product	product	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

STRIBILD	NNP	stribild	stribild	stribild	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
for	IN	for	for	for	N	O
coadministration	NN	coadministration	coadministration	coadministr	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
:	:	:	:	:	N	O

cobicistat	NN	cobicistat	cobicistat	cobicistat	N	O
(	(	(	(	(	N	O
TYBOST	NNP	tybost	tybost	tybost	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O

elvitegravir	NN	elvitegravir	elvitegravir	elvitegravir	N	O
(	(	(	(	(	N	O
VITEKTA	NNP	vitekta	vitekta	vitekta	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O

products	NNS	products	product	product	N	O
containing	VBG	containing	containing	contain	N	O
emtricitabine	NN	emtricitabine	emtricitabine	emtricitabin	N	O
or	CC	or	or	or	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
(	(	(	(	(	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
,	,	,	,	,	N	O
COMPLERA	NNP	complera	complera	complera	N	O
,	,	,	,	,	N	O
EMTRIVA	NNP	emtriva	emtriva	emtriva	N	O
,	,	,	,	,	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
,	,	,	,	,	N	O
VIREAD	NNP	viread	viread	viread	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O

products	NNS	products	product	product	N	O
containing	VBG	containing	containing	contain	N	O
lamivudine	NN	lamivudine	lamivudine	lamivudin	N	O
(	(	(	(	(	N	O
COMBIVIR	NNP	combivir	combivir	combivir	N	O
,	,	,	,	,	N	O
EPIVIR	NNP	epivir	epivir	epivir	N	O
,	,	,	,	,	N	O
EPIVIR	NNP	epivir	epivir	epivir	N	O
-	:	-	-	-	N	O
HBV	NNP	hbv	hbv	hbv	N	O
,	,	,	,	,	N	O
EPZICOM	NNP	epzicom	epzicom	epzicom	N	O
,	,	,	,	,	N	O
TRIUMEQ	NNP	triumeq	triumeq	triumeq	N	O
,	,	,	,	,	N	O
TRIZIVIR	NNP	trizivir	trizivir	trizivir	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O

adefovir	NN	adefovir	adefovir	adefovir	N	O
dipivoxil	NN	dipivoxil	dipivoxil	dipivoxil	N	O
(	(	(	(	(	N	O
HEPSERA	NNP	hepsera	hepsera	hepsera	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O

products	NNS	products	product	product	N	O
containing	VBG	containing	containing	contain	N	O
ritonavir	NN	ritonavir	ritonavir	ritonavir	N	O
(	(	(	(	(	N	O
NORVIR	NNP	norvir	norvir	norvir	N	O
,	,	,	,	,	N	O
KALETRA	NNP	kaletra	kaletra	kaletra	N	O
)	)	)	)	)	N	O

5.5	CD	5.5	5.5	5.5	N	O
Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNPS	reactions	reaction	reaction	N	O
or	CC	or	or	or	N	O
Loss	NNP	loss	loss	loss	N	O
of	IN	of	of	of	N	O
Virologic	NNP	virologic	virologic	virolog	N	O
Response	NNP	response	response	respons	N	O
Due	NNP	due	due	due	N	O
to	TO	to	to	to	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O

The	DT	the	the	the	N	O

concomitant	NN	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
may	MD	may	may	may	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
known	NN	known	known	known	N	O
or	CC	or	or	or	N	O
potentially	RB	potentially	potentially	potenti	N	O
significant	JJ	significant	significant	signific	N	O
drug	NN	drug	drug	drug	N	O
interactions	NNS	interactions	interaction	interact	N	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
[	VB	[	[	[	N	O
see	VB	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.5	CD	7.5	7.5	7.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
:	:	:	:	:	N	O

Loss	NNP	loss	loss	loss	N	O
of	IN	of	of	of	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
and	CC	and	and	and	N	O
possible	JJ	possible	possible	possibl	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
resistance	NN	resistance	resistance	resist	N	O
.	.	.	.	.	N	O

Possible	JJ	possible	possible	possibl	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
from	IN	from	from	from	N	O
greater	JJR	greater	greater	greater	N	O
exposures	NNS	exposures	exposure	exposur	N	O
of	IN	of	of	of	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
drugs	NNS	drugs	drug	drug	N	O
.	.	.	.	.	N	O

See	VB	see	see	see	N	O
Table	JJ	table	table	tabl	N	O
6	CD	6	6	6	N	O
for	IN	for	for	for	N	O
steps	NNS	steps	step	step	N	O
to	TO	to	to	to	N	O
prevent	VB	prevent	prevent	prevent	N	O
or	CC	or	or	or	N	O
manage	VB	manage	manage	manag	N	O
these	DT	these	these	these	N	O
possible	JJ	possible	possible	possibl	N	O
and	CC	and	and	and	N	O
known	JJ	known	known	known	N	O
significant	JJ	significant	significant	signific	N	O
drug	NN	drug	drug	drug	N	O
interactions	NNS	interactions	interaction	interact	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
dosing	VBG	dosing	dosing	dose	N	O
recommendations	NNS	recommendations	recommendation	recommend	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.5	CD	7.5	7.5	7.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
potential	NN	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
drug	NN	drug	drug	drug	N	O
interactions	NNS	interactions	interaction	interact	N	O
prior	VBP	prior	prior	prior	N	O
to	TO	to	to	to	N	O
and	CC	and	and	and	N	O
during	IN	during	during	dure	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
therapy	NN	therapy	therapy	therapi	N	O
;	:	;	;	;	N	O
review	NN	review	review	review	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
during	IN	during	during	dure	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
therapy	NN	therapy	therapy	therapi	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
monitor	VB	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
concomitant	NN	concomitant	concomitant	concomit	N	O
drugs	NNS	drugs	drug	drug	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O

Bone	NNP	bone	bone	bone	N	O
Effects	NNPS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
Tenofovir	NNP	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O

Bone	NNP	bone	bone	bone	N	O
Mineral	NNP	mineral	mineral	miner	N	O
Density	NNP	density	density	densiti	N	O
:	:	:	:	:	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
infected	JJ	infected	infected	infect	N	O
adults	NNS	adults	adult	adult	N	O
,	,	,	,	,	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
(	(	(	(	(	N	O
a	DT	a	a	a	N	O
component	NN	component	component	compon	N	O
of	IN	of	of	of	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
slightly	RB	slightly	slightly	slightli	N	O
greater	JJR	greater	greater	greater	N	O
decreases	NNS	decreases	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
bone	JJ	bone	bone	bone	N	I-AdverseReaction
mineral	JJ	mineral	mineral	miner	N	I-AdverseReaction
density	NN	density	density	densiti	N	I-AdverseReaction
(	(	(	(	(	N	O
BMD	NNP	bmd	bmd	bmd	N	I-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
increases	VBZ	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
biochemical	JJ	biochemical	biochemical	biochem	N	I-AdverseReaction
markers	NNS	markers	marker	marker	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
bone	NN	bone	bone	bone	N	I-AdverseReaction
metabolism	NN	metabolism	metabolism	metabol	N	I-AdverseReaction
,	,	,	,	,	N	O
suggesting	VBG	suggesting	suggesting	suggest	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
bone	NN	bone	bone	bone	N	I-AdverseReaction
turnover	NN	turnover	turnover	turnov	N	I-AdverseReaction
relative	VBP	relative	relative	rel	N	O
to	TO	to	to	to	N	O
comparators	NNS	comparators	comparators	compar	N	O
.	.	.	.	.	N	O

Serum	NNP	serum	serum	serum	N	O
parathyroid	VBP	parathyroid	parathyroid	parathyroid	N	O
hormone	NN	hormone	hormone	hormon	N	O
levels	NNS	levels	level	level	N	O
and	CC	and	and	and	N	O
1.25	CD	1.25	1.25	1.25	N	O
Vitamin	NNP	vitamin	vitamin	vitamin	N	O
D	NNP	d	d	d	N	O
levels	NNS	levels	level	level	N	O
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
higher	JJR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
additional	JJ	additional	additional	addit	N	O
information	NN	information	information	inform	N	O
,	,	,	,	,	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
consult	VB	consult	consult	consult	N	O
the	DT	the	the	the	N	O
VIREAD	NNP	viread	viread	viread	N	O
prescribing	NN	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
-	:	-	-	-	N	O
associated	VBN	associated	associated	associ	N	O
changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
BMD	NNP	bmd	bmd	bmd	N	O
and	CC	and	and	and	N	O
biochemical	JJ	biochemical	biochemical	biochem	N	O
markers	NNS	markers	marker	marker	N	O
on	IN	on	on	on	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
bone	NN	bone	bone	bone	N	O
health	NN	health	health	health	N	O
and	CC	and	and	and	N	O
future	JJ	future	future	futur	N	O
fracture	NN	fracture	fracture	fractur	Y	O
risk	NN	risk	risk	risk	N	O
are	VBP	are	are	are	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Assessment	NN	assessment	assessment	assess	N	O
of	IN	of	of	of	N	O
BMD	NNP	bmd	bmd	bmd	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
for	IN	for	for	for	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
infected	JJ	infected	infected	infect	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
pathologic	JJ	pathologic	pathologic	patholog	N	O
bone	NN	bone	bone	bone	N	O
fracture	NN	fracture	fracture	fractur	Y	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
or	CC	or	or	or	N	O
bone	NN	bone	bone	bone	N	O
loss	NN	loss	loss	loss	N	O
.	.	.	.	.	N	O

Although	IN	although	although	although	N	O
the	DT	the	the	the	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
supplementation	NN	supplementation	supplementation	supplement	N	O
with	IN	with	with	with	N	O
calcium	NN	calcium	calcium	calcium	Y	O
and	CC	and	and	and	N	O
vitamin	NN	vitamin	vitamin	vitamin	N	O
D	NNP	d	d	d	N	O
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	O
studied	VBN	studied	studied	studi	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
supplementation	NN	supplementation	supplementation	supplement	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
beneficial	JJ	beneficial	beneficial	benefici	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
bone	NN	bone	bone	bone	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
are	VBP	are	are	are	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
then	RB	then	then	then	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
consultation	NN	consultation	consultation	consult	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
obtained	VBN	obtained	obtained	obtain	N	O
.	.	.	.	.	N	O

Mineralization	NN	mineralization	mineralization	miner	N	O
Defects	NNS	defects	defect	defect	N	O
:	:	:	:	:	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
osteomalacia	NN	osteomalacia	osteomalacia	osteomalacia	Y	B-AdverseReaction
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
proximal	JJ	proximal	proximal	proxim	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
tubulopathy	NN	tubulopathy	tubulopathy	tubulopathi	N	I-AdverseReaction
,	,	,	,	,	N	O
manifested	VBN	manifested	manifested	manifest	N	O
as	IN	as	a	as	N	O
bone	NN	bone	bone	bone	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
or	CC	or	or	or	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremities	NNS	extremities	extremity	extrem	N	I-AdverseReaction
and	CC	and	and	and	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	B-Factor
contribute	VB	contribute	contribute	contribut	N	O
to	TO	to	to	to	N	O
fractures	NNS	fractures	fracture	fractur	N	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Arthralgias	NNP	arthralgias	arthralgia	arthralgia	N	B-AdverseReaction
and	CC	and	and	and	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
or	CC	or	or	or	N	O
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
proximal	JJ	proximal	proximal	proxim	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
tubulopathy	NN	tubulopathy	tubulopathy	tubulopathi	N	I-AdverseReaction
.	.	.	.	.	N	O

Hypophosphatemia	NNP	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	O
and	CC	and	and	and	N	O
osteomalacia	RB	osteomalacia	osteomalacia	osteomalacia	Y	O
secondary	JJ	secondary	secondary	secondari	N	O
to	TO	to	to	to	N	O
proximal	JJ	proximal	proximal	proxim	N	O
renal	JJ	renal	renal	renal	N	O
tubulopathy	NN	tubulopathy	tubulopathy	tubulopathi	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
renal	JJ	renal	renal	renal	N	O
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	O
who	WP	who	who	who	N	O
present	VBP	present	present	present	N	O
with	IN	with	with	with	N	O
persistent	NN	persistent	persistent	persist	N	O
or	CC	or	or	or	N	O
worsening	VBG	worsening	worsening	worsen	N	O
bone	NN	bone	bone	bone	N	O
or	CC	or	or	or	N	O
muscle	NN	muscle	muscle	muscl	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
while	IN	while	while	while	N	O
receiving	VBG	receiving	receiving	receiv	N	O
products	NNS	products	product	product	N	O
containing	VBG	containing	containing	contain	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
DF	NNP	df	df	df	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Fat	NNP	fat	fat	fat	N	O
Redistribution	NNP	redistribution	redistribution	redistribut	N	O

Redistribution	NNP	redistribution	redistribution	redistribut	N	B-AdverseReaction
accumulation	NN	accumulation	accumulation	accumul	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
fat	JJ	fat	fat	fat	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
central	JJ	central	central	central	N	B-AdverseReaction
obesity	NN	obesity	obesity	obes	Y	I-AdverseReaction
,	,	,	,	,	N	O
dorsocervical	JJ	dorsocervical	dorsocervical	dorsocerv	N	B-AdverseReaction
fat	NN	fat	fat	fat	N	I-AdverseReaction
enlargement	NN	enlargement	enlargement	enlarg	N	I-AdverseReaction
(	(	(	(	(	N	O
buffalo	JJ	buffalo	buffalo	buffalo	N	B-AdverseReaction
hump	NN	hump	hump	hump	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	I-AdverseReaction
wasting	NN	wasting	wasting	wast	Y	I-AdverseReaction
,	,	,	,	,	N	O
facial	JJ	facial	facial	facial	N	B-AdverseReaction
wasting	NN	wasting	wasting	wast	Y	I-AdverseReaction
,	,	,	,	,	N	O
breast	NN	breast	breast	breast	N	B-AdverseReaction
enlargement	NN	enlargement	enlargement	enlarg	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
"	NNP	"	"	"	N	O
cushingoid	VBP	cushingoid	cushingoid	cushingoid	Y	B-AdverseReaction
appearance	NN	appearance	appearance	appear	N	I-AdverseReaction
"	NNS	"	"	"	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
and	CC	and	and	and	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
consequences	NNS	consequences	consequence	consequ	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
are	VBP	are	are	are	N	O
currently	RB	currently	currently	current	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Immune	NNP	immune	immune	immun	N	O
Reconstitution	NNP	reconstitution	reconstitution	reconstitut	N	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
reconstitution	NN	reconstitution	reconstitution	reconstitut	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
combination	NN	combination	combination	combin	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
STRIBILD	NNP	stribild	stribild	stribild	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
initial	JJ	initial	initial	initi	N	O
phase	NN	phase	phase	phase	N	O
of	IN	of	of	of	N	O
combination	NN	combination	combination	combin	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
immune	JJ	immune	immune	immun	N	O
system	NN	system	system	system	N	O
responds	NNS	responds	responds	respond	N	O
may	MD	may	may	may	N	B-Factor
develop	VB	develop	develop	develop	N	O
an	DT	an	an	an	N	O
inflammatory	JJ	inflammatory	inflammatory	inflammatori	N	O
response	NN	response	response	respons	N	O
to	TO	to	to	to	N	O
indolent	NN	indolent	indolent	indol	N	O
or	CC	or	or	or	N	O
residual	JJ	residual	residual	residu	N	B-AdverseReaction
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
[	VBP	[	[	[	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
Mycobacterium	NNP	mycobacterium	mycobacterium	mycobacterium	N	B-AdverseReaction
avium	NN	avium	avium	avium	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
cytomegalovirus	NN	cytomegalovirus	cytomegalovirus	cytomegaloviru	N	B-AdverseReaction
,	,	,	,	,	N	O
Pneumocystis	NNP	pneumocystis	pneumocystis	pneumocysti	N	B-AdverseReaction
jirovecii	NN	jirovecii	jirovecii	jirovecii	N	I-AdverseReaction
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	I-AdverseReaction
(	(	(	(	(	N	O
PCP	NNP	pcp	pcp	pcp	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
]	NN	]	]	]	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
necessitate	VB	necessitate	necessitate	necessit	N	O
further	JJ	further	further	further	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Autoimmune	NNP	autoimmune	autoimmune	autoimmun	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
Graves	NNS	graves	graf	grave	N	B-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
polymyositis	NN	polymyositis	polymyositis	polymyos	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Guillain	NNP	guillain	guillain	guillain	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Barre	NNP	barre	barre	barr	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
to	TO	to	to	to	N	O
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
setting	NN	setting	setting	set	N	O
of	IN	of	of	of	N	O
immune	JJ	immune	immune	immun	N	O
reconstitution	NN	reconstitution	reconstitution	reconstitut	N	O
,	,	,	,	,	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
is	VBZ	is	is	is	N	O
more	RBR	more	more	more	N	O
variable	JJ	variable	variable	variabl	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
many	JJ	many	many	mani	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

